Gain Therapeutics, Inc. (GANX)
NASDAQ:GANX
Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$2.13
-$0.01(-0.44%)
At close: 4:00 PM EST
$2.13
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)631.85K
Market Cap
$71.66M
Enterprise Value$66.93M
Total Cash (Recent Filing)$16.54M
Total Debt (Recent Filing)$672.30K
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding42,654,037
10 Day Avg. Volume662,263
30 Day Avg. Volume631,850
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$7.20Price Target Upside238.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Phase 1b GT-02287 DataGT-02287's reported favorable safety, strong patient retention (16 of 19 continuing) and large CSF glucosylsphingosine reductions materially de-risk the lead program. Durable safety and biomarker response support progression to later trials and increase partner and investor confidence in development prospects.
Clinical Signals Tied To Functional OutcomesReported stable MDS‑UPDRS scores and a 6.7‑point advantage in high‑GluSph patients, plus reductions in DOPA decarboxylase, suggest target engagement with associated functional benefit. A biomarker‑linked clinical signal increases the probability of meaningful, durable efficacy and supports translational validity for the GCase approach.
Pipeline Expansion With Brain-penetrant CandidateAdvancing GT‑04686 toward IND‑enabling work demonstrates the platform can generate additional brain‑penetrant GCase modulators. Building a multi‑asset pipeline reduces binary risk around a single program, increases strategic optionality for partnerships, and supports longer‑term value creation.
Bears Say
Pre-revenue With Large LossesA pre‑revenue profile with a TTM net loss near $21.2M means the company currently cannot self‑fund growth from operations. Persistent large losses elevate financing risk, constrain strategic flexibility, and increase the probability of dilutive capital raises that can impair long‑term shareholder returns.
Material Negative Operating Cash FlowOperating and free cash flow are materially negative (around -$19.4M TTM) and appear steady rather than improving. Weak cash generation forces reliance on external financing, can delay or compress R&D timelines if capital is constrained, and burdens management with recurring fundraising needs.
Declining Equity And Negative ReturnsEquity erosion from ~$18.6M to ~$14.0M and a negative TTM ROE (~-2.38) indicate capital is being consumed rather than compounded. Declining equity and negative returns weaken balance sheet resilience, heighten funding vulnerability, and raise the likelihood of future dilution to sustain development programs.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $71.66M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.008.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 42,654,037 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (238.03% Upside)
$7.20 (238.03% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.66%
12-Months-Change
Fundamentals
Return on Equity
-201.43%
Trailing 12-Months
Asset Growth
61.20%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.20
▲(238.03% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.00%
Insiders
1.76% Mutual Funds
4.13% Other Institutional Investors
89.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---